Objective(s): Risk-stratified thromboprophylaxis is recommended for oncology patients with a Khorana risk score (KS) ≥ 2 receiving cancer-directed therapy. We describe a quality improvement (QI) initiative designed to increase adherence to thromboprophylaxis guidelines for patients with gynecologic malignancies initiating outpatient treatment.
Methods: Provider awareness and documentation of venous thromboembolism (VTE) risk assessment and thromboprophylaxis eligibility were identified as key QI drivers. Starting May 2021, a KS calculator and thromboprophylaxis algorithm were incorporated into outpatient documentation templates. Patients with gynecologic malignancies initiating outpatient therapy from January - December 2021 were eligible. The primary process measure was the percentage of patients with KS eligibility documented each month during the baseline (Jan - Apr) versus implementation (May - Dec) periods. Rate of appropriate thromboprophylaxis initiation and incidence of VTE served as outcome measures. Incidence of adverse bleeding events served as the balancing measure.
Results: 337 patients accounted for the initiation of 383 treatment regimens, including 128 in the baseline period and 255 in the implementation period. KS documentation increased significantly between the baseline and implementation periods (7% vs 62.4%, p < 0.001). 73 of the 177 eligible patients (46.2%; 166 unique patients) had appropriate documentation; of these, 57 initiated thromboprophylaxis. There was no difference in VTE rates or adverse bleeding events between eligible patients who initiated thromboprophylaxis compared with those who did not (12.3% vs 15.6%; p = 0.65 and 7.0% vs 8.2%; p = 1.0, respectively).
Conclusion(s): This QI initiative resulted in greater adherence to risk-stratified thromboprophylaxis guidelines. No bleeding signals were identified. Studies addressing cost, medication adherence, and long-term outcomes are necessary.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ygyno.2022.11.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Testing of a risk-stratified patient decision aid to facilitate shared decision-making for extended postoperative thromboprophylaxis after major abdominal surgery for cancer.
Can J Surg
August 2024
From the Faculty of Medicine, University of Ottawa, Ottawa, Ont. (Ivankovic, Delisle, Balaa, Dingley); the School of Nursing, University of Ottawa, Ottawa, Ont. (Stacey); the Ottawa Hospital Research Institute, Ottawa, Ont. (Stacey, Abou-Khalil, Bertens, Martel, Nessim, Tadros, Carrier, Auer); the Department of Surgery, University of Ottawa, Ottawa, Ont. (Abou-Khalil, Bertens, Martel, Nessim, Tadros, Auer); the Division of Urology, Department of Surgery, University of Toronto, Toronto, Ont. (McAlpine); and the Department of Medicine, University of Ottawa, Ottawa, Ont. (Carrier)
Background: Use of extended pharmacologic thromboprophylaxis after major abdominopelvic cancer surgery should depend on best-available scientific evidence and patients' informed preferences. We developed a risk-stratified patient decision aid to facilitate shared decision-making and sought to evaluate its effect on decision-making quality regarding use of extended thromboprophylaxis.
Methods: We enrolled patients undergoing major abdominopelvic cancer surgery at an academic tertiary care centre in this pre-post study.
A More Selective vs a Standard Risk-Stratified, Heparin-Based, Obstetric Thromboprophylaxis Protocol.
JAMA
July 2024
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Center for Women's Reproductive Health at the University of Alabama at Birmingham.
Importance: In 2016, our institution adopted a pregnancy-related venous thromboembolism (VTE) prophylaxis protocol based on American College of Obstetricians and Gynecologists guidelines that recommended postpartum heparin-based chemoprophylaxis (enoxaparin) based on a risk-stratified algorithm. In response to increased wound hematomas without significant reduction in VTE using this protocol, a more selective risk-stratified approach was adopted in 2021.
Objective: To evaluate outcomes of the more selective risk-stratified approach to heparin-based obstetric thromboprophylaxis (enoxaparin) protocol.
Invasive Mechanical Ventilation and Risk of Hospital-Acquired Venous Thromboembolism.
Respir Care
October 2024
Department of Anesthesia and Critical Care Medicine, Johns Hopkins All Children's Hospital, St. Petersburg, Florida.
Background: This study sought to estimate the overall cumulative incidence and odds of Hospital-acquired venous thromboembolism (VTE) among critically ill children with and without exposure to invasive ventilation. In doing so, we also aimed to describe the temporal relationship between invasive ventilation and hospital-acquired VTE development.
Methods: We performed a retrospective cohort study using Virtual Pediatric Systems (VPS) data from 142 North American pediatric ICUs among children < 18 y of age from January 1, 2016-December 31, 2022.
Predictive accuracy of boosted regression model in estimating risk of venous thromboembolism following minimally invasive radical surgery in pharmacological prophylaxis-naïve men with prostate cancer.
World J Surg Oncol
February 2024
Academic Urology Unit, Division of Imaging Sciences and Technology, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY, UK.
Background: Venous thromboembolism (VTE) is a potentially life-threatening but preventable complication after urological surgery. Physicians are faced with the challenges of weighing the risks and benefits of thromboprophylaxis given scanty evidence for or against and practice variation worldwide.
Objective: The primary objective of the study was to explore the possibility of a risk-stratified approach for thromboembolism prophylaxis following radical prostatectomy.
Risk-stratified thromboprophylaxis effects of aspirin versus low-molecular-weight heparin in orthopedic trauma patients: A secondary analysis of the PREVENT CLOT trial.
J Trauma Acute Care Surg
April 2024
From the Department of Orthopaedics (N.N.O.'H., R.V.O.'T., G.P.S.), R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine; Department of Health Policy and Management (K.P.F., R.C.C., A.R.C.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Department of Surgery (J.C.), University of California in San Francisco, San Francisco, California; Department of Surgery (E.R.H.), Johns Hopkins Hospital, Baltimore, Maryland; Department of Orthopaedics and Sports Medicine (R.F.), University of Washington, Seattle, Washington; Department of Surgery (A.C.), Carolinas Medical Center, Atrium Health, Charlotte, North Carolina; Department of Orthopaedic Surgery (W.T.O.), Vanderbilt University Medical Center, Nashville, Tennessee; Department of Orthopaedics (G.G.), Inova Fairfax Hospital, Fairfax, Virginia; Department of Surgery (M.E.K.), University of Mississippi, Jackson, Mississippi; PREVENT CLOT Patient Stakeholder, (D.M.); and Program in Trauma/Department of Surgery (D.M.S.), R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, Maryland.
Background: The PREVENT CLOT trial concluded that thromboprophylaxis with aspirin was noninferior to low-molecular-weight heparin (LMWH) in preventing death after orthopedic trauma. However, it was unclear if these results applied to patients at highest risk of thrombosis. Therefore, we assessed if the effect of aspirin versus LMWH differed based on patients' baseline risk of venous thromboembolism (VTE).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!